A hundred thousand dollars is not a lot of money in venture terms. It buys a fraction of a Series A round in San Francisco, barely covers a year of engineering salaries in Seoul, and would not get a second meeting with most growth-stage funds. But in the context of femtech startups operating in emerging markets, a $100,000 injection can be the difference between a promising prototype and a company that actually reaches patients.
That is the premise behind a new funding call from ICTworks, which is inviting early-stage femtech ventures in low- and middle-income countries to compete for a $100,000 prize. The details are straightforward enough: startups working on women’s health technology, from reproductive care to maternal monitoring to menstrual health tracking, can apply. What matters more is what the competition signals about where femtech is heading next.
For years, the femtech conversation has been dominated by a handful of wealthy-market players. Flo, Clue, and a clutch of fertility and menopause apps built large user bases across North America and Europe, raised serious capital, and occasionally stumbled into privacy controversies that made headlines. The sector’s growth story has been real, but geographically narrow. Most of the world’s women live outside those markets, and their health needs have been served by a thin layer of NGOs, public health programs, and informal care.
That gap is both a problem and an opportunity. Investors who have looked closely at emerging markets point out that the constraints are different. Smartphone penetration is high but data costs are real. Regulatory pathways vary wildly from country to country. Payment infrastructure is fragmented, and willingness to pay out of pocket for health services is limited in many places. A femtech product designed for a subscription-first, app-store-centric market often does not translate.
What does translate, according to founders and public health researchers who work in these regions, is anything that reduces friction in care delivery. Remote maternal monitoring that connects community health workers to obstetricians. Diagnostic tools that work offline or on low-bandwidth connections. Supply chain software that helps clinics avoid stockouts of contraceptives or prenatal supplements. These are unglamorous products compared to a sleek period-tracking app, but they address problems that kill people.
The funding landscape for this kind of work has been improving, slowly. Development finance institutions, impact funds, and a handful of corporate venture arms have started writing checks to femtech startups in Africa, South Asia, and Latin America. Grand Challenges-style competitions and accelerator programs have proliferated. Still, the amounts are small relative to the scale of the need, and the gap between pilot funding and sustainable revenue remains a valley of death for many founders.
A $100,000 prize will not solve that structural problem. What it can do is provide runway for a small team to prove a model, hire locally, and generate the kind of evidence that unlocks the next round. Competition organizers tend to design these programs with that logic in mind, pairing cash with mentorship and visibility. Whether the winners convert that into durable businesses depends on factors no prize can control: reimbursement policy, distribution partnerships, and the willingness of health systems to adopt new tools.
There is also a cautionary note worth sounding. Femtech has a data problem, and it is not confined to rich countries. Apps that collect intimate health information have repeatedly been found to share data with advertisers or third parties. In markets where regulatory oversight is thinner and users may be less aware of how their data travels, the risks compound. Any startup building in this space, especially one hoping to win a high-profile prize, should expect scrutiny of its privacy practices. The best defense is to build consent and data minimization in from the start rather than bolting them on after a reporter calls.
The broader context matters too. AI is reshaping health diagnostics at a pace that regulators are struggling to match, and femtech is not immune. Models trained on skewed datasets have produced worse outcomes for women in everything from cardiac care to symptom triage. Startups working in emerging markets have an opportunity to build better datasets, but only if they are deliberate about it and if the communities they serve trust them enough to participate.
None of this makes for a tidy narrative. The femtech sector’s next chapter will not be written by a single $100,000 check. It will be written by dozens of small companies grinding through regulatory approvals, distribution deals, and the unglamorous work of earning patient trust in places where health systems are already stretched thin. Competitions like this one matter less for the money than for the signal they send: that investors and funders are finally looking beyond the obvious markets, and that the problems worth solving are not limited to the places with the loudest venture ecosystems.